NO327317B1 - Vektor for fremstillingen av IL-4 og IL-4-mutanter, DNA-konstruksjon og E.coli. - Google Patents
Vektor for fremstillingen av IL-4 og IL-4-mutanter, DNA-konstruksjon og E.coli. Download PDFInfo
- Publication number
- NO327317B1 NO327317B1 NO20000262A NO20000262A NO327317B1 NO 327317 B1 NO327317 B1 NO 327317B1 NO 20000262 A NO20000262 A NO 20000262A NO 20000262 A NO20000262 A NO 20000262A NO 327317 B1 NO327317 B1 NO 327317B1
- Authority
- NO
- Norway
- Prior art keywords
- vector
- gene
- expression
- mutants
- plasmid
- Prior art date
Links
- 102000004388 Interleukin-4 Human genes 0.000 title claims description 45
- 108090000978 Interleukin-4 Proteins 0.000 title claims description 45
- 239000013598 vector Substances 0.000 title claims description 18
- 241000588724 Escherichia coli Species 0.000 title claims description 11
- 238000010276 construction Methods 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 238000013518 transcription Methods 0.000 claims description 12
- 230000035897 transcription Effects 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108091081024 Start codon Proteins 0.000 claims 1
- 229940028885 interleukin-4 Drugs 0.000 description 37
- 239000013612 plasmid Substances 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 22
- 238000000034 method Methods 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 108700010070 Codon Usage Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010054278 Lac Repressors Proteins 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 101150109249 lacI gene Proteins 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101100398597 Botryotinia fuckeliana lcc1 gene Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 241000701867 Enterobacteria phage T7 Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000701988 Escherichia virus T5 Species 0.000 description 2
- 101100068374 Gibberella zeae (strain ATCC MYA-4620 / CBS 123657 / FGSC 9075 / NRRL 31084 / PH-1) GIP1 gene Proteins 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 101150078341 rop gene Proteins 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000908115 Bolivar Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 101150006320 trpR gene Proteins 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/72—Expression systems using regulatory sequences derived from the lac-operon
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99100967A EP1022339B1 (de) | 1999-01-20 | 1999-01-20 | Plasmide, deren Konstruktion und Anwendung zur Herstellung von Interleukin-4 und dessen Muteine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20000262D0 NO20000262D0 (no) | 2000-01-19 |
| NO20000262L NO20000262L (no) | 2000-07-21 |
| NO327317B1 true NO327317B1 (no) | 2009-06-08 |
Family
ID=8237378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000262A NO327317B1 (no) | 1999-01-20 | 2000-01-19 | Vektor for fremstillingen av IL-4 og IL-4-mutanter, DNA-konstruksjon og E.coli. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6506590B1 (de) |
| EP (1) | EP1022339B1 (de) |
| JP (2) | JP2000210091A (de) |
| KR (1) | KR100665148B1 (de) |
| AT (1) | ATE334202T1 (de) |
| AU (1) | AU772897B2 (de) |
| CA (1) | CA2294575C (de) |
| CZ (1) | CZ294279B6 (de) |
| DE (1) | DE69929638T2 (de) |
| DK (1) | DK1022337T3 (de) |
| ES (1) | ES2269027T3 (de) |
| HU (1) | HU224491B1 (de) |
| NO (1) | NO327317B1 (de) |
| PT (1) | PT1022337E (de) |
| SK (1) | SK285603B6 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10022258A1 (de) | 2000-05-08 | 2001-11-15 | Bayer Ag | Reinigung von Proteineinschlusskörpern durch Querstrom-Mikrofiltration |
| KR100443570B1 (ko) * | 2001-07-31 | 2004-08-09 | 크레아젠 주식회사 | 재조합 인간 인터루킨-4의 제조방법 |
| EP1314739A1 (de) | 2001-11-22 | 2003-05-28 | Bayer Ag | Verfahren zur Renaturierung rekombinanter, Disulfid-enthaltender Proteine bei hohen Proteinkonzentrationen in Gegenwart von Aminen |
| JP2006055082A (ja) * | 2004-08-20 | 2006-03-02 | National Institute Of Advanced Industrial & Technology | 発光甲虫由来赤色発光酵素安定体の生産及び精製法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4689406A (en) * | 1983-08-10 | 1987-08-25 | Amgen | Enhancement of microbial expression of polypeptides |
| AU597951B2 (en) * | 1986-03-27 | 1990-06-14 | Monsanto Company | Enhanced protein production in bacteria by employing a novel ribosome binding site |
| ATE123526T1 (de) * | 1987-08-17 | 1995-06-15 | Hoffmann La Roche | Hochreprimierbare expressionskontrollsequenzen. |
| FR2724665B1 (fr) * | 1994-09-16 | 1996-12-20 | Rhone Poulenc Rorer Sa | Procede de production de proteines recombinantes, plasmides et cellules modifiees |
| MY124565A (en) * | 1996-07-19 | 2006-06-30 | Bayer Corp | High-affinity interleukin-4-muteins |
-
1999
- 1999-01-20 EP EP99100967A patent/EP1022339B1/de not_active Expired - Lifetime
- 1999-01-20 DE DE69929638T patent/DE69929638T2/de not_active Expired - Lifetime
-
2000
- 2000-01-07 AT AT00100129T patent/ATE334202T1/de active
- 2000-01-07 DK DK00100129T patent/DK1022337T3/da active
- 2000-01-07 ES ES00100129T patent/ES2269027T3/es not_active Expired - Lifetime
- 2000-01-07 PT PT00100129T patent/PT1022337E/pt unknown
- 2000-01-14 JP JP2000006477A patent/JP2000210091A/ja active Pending
- 2000-01-14 US US09/483,419 patent/US6506590B1/en not_active Expired - Fee Related
- 2000-01-17 CA CA002294575A patent/CA2294575C/en not_active Expired - Fee Related
- 2000-01-19 KR KR1020000002310A patent/KR100665148B1/ko not_active IP Right Cessation
- 2000-01-19 CZ CZ2000214A patent/CZ294279B6/cs not_active IP Right Cessation
- 2000-01-19 NO NO20000262A patent/NO327317B1/no not_active IP Right Cessation
- 2000-01-19 SK SK76-2000A patent/SK285603B6/sk unknown
- 2000-01-20 AU AU12507/00A patent/AU772897B2/en not_active Ceased
- 2000-01-20 HU HU0000185A patent/HU224491B1/hu not_active IP Right Cessation
-
2010
- 2010-08-27 JP JP2010190917A patent/JP2010284174A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| HU224491B1 (hu) | 2005-09-28 |
| DK1022337T3 (da) | 2006-11-06 |
| AU772897B2 (en) | 2004-05-13 |
| ATE334202T1 (de) | 2006-08-15 |
| DE69929638T2 (de) | 2006-09-21 |
| CA2294575C (en) | 2009-04-07 |
| SK762000A3 (en) | 2000-08-14 |
| HU0000185D0 (en) | 2000-04-28 |
| EP1022339B1 (de) | 2006-02-01 |
| PT1022337E (pt) | 2006-11-30 |
| HUP0000185A2 (en) | 2002-09-28 |
| KR20000053523A (ko) | 2000-08-25 |
| NO20000262D0 (no) | 2000-01-19 |
| KR100665148B1 (ko) | 2007-01-09 |
| DE69929638D1 (de) | 2006-04-13 |
| CZ2000214A3 (cs) | 2000-08-16 |
| JP2000210091A (ja) | 2000-08-02 |
| CA2294575A1 (en) | 2000-07-20 |
| CZ294279B6 (cs) | 2004-11-10 |
| EP1022339A1 (de) | 2000-07-26 |
| ES2269027T3 (es) | 2007-04-01 |
| US6506590B1 (en) | 2003-01-14 |
| AU1250700A (en) | 2000-07-27 |
| NO20000262L (no) | 2000-07-21 |
| JP2010284174A (ja) | 2010-12-24 |
| SK285603B6 (sk) | 2007-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sharma et al. | Temporal and spatial regulation of the symbiotic genes of Rhizobium meliloti in planta revealed by transposon Tn5-gusA. | |
| US6291245B1 (en) | Host-vector system | |
| US6117651A (en) | Expression vectors | |
| NO324920B1 (no) | Fremgangsmate for a sekretere et aktuelt heterologt polypeptid i en celle, nukleinsyre som koder for en sekresjonssignalsekvensvariant av STII og en variant av STII-sekresjonssignalsekvensen. | |
| Yasunobu et al. | Genetic characterization of the gene hupB encoding the HU-1 protein of Escherichia coli | |
| Meyer et al. | Properties of R1162, a broad-host-range, high-copy-number plasmid | |
| Beard et al. | A stable and efficient transformation system for Butyrivibrio fibrisolvens OB156 | |
| Davis et al. | Nucleotide sequence of the mannitol (mtl) operon in Escherichia coli | |
| Puyet et al. | Characterization of the Streptococcus pneumoniae maltosaccharide regulator MalR, a member of the LacI-GalR family of repressors displaying distinctive genetic features. | |
| EP0195303B1 (de) | Plasmidvektoren zur Expression in Escherichia coli und/oder Bacillus subtilis | |
| NO327317B1 (no) | Vektor for fremstillingen av IL-4 og IL-4-mutanter, DNA-konstruksjon og E.coli. | |
| MXPA04005717A (es) | Sistema de expresion. | |
| EP0688870A1 (de) | Hochgereinigte rekombinante reverse Transkriptase | |
| US6165746A (en) | Preventing endogenous aminopeptidase mediated n-terminal amino acid cleavage during expression of foreign genes in bacteria | |
| EP1022337B1 (de) | Plasmide, deren Konstruktion und deren Verwendung zur Herstellung von Interleukin-4 und Interleukin-4 Muteine | |
| Roytrakul et al. | A Rapid and Simple Method for Construction and Expression of a Synthetic | |
| AU663139B2 (en) | A novel translational activating sequence | |
| Jackson et al. | Cloning and analysis of pif, replication and leading regions of the F plasmid | |
| Ouimet et al. | Transcription reporters that shuttle cloned DNA between high-copy Escherichia coli plasmids and low-copy broad-host-range plasmids | |
| AU2001251342A1 (en) | Ketogulonigenium endogenous plasmids | |
| EP0471514A2 (de) | Verbesserte Bakteriophage-lambda-pL-Promotoren | |
| HUT62336A (en) | Process for increasing structural stability of recombinant dna expression vectors | |
| WO1991006656A1 (en) | Promoter, expression vector and polypeptide synthesis | |
| Burden et al. | Designing a Cloning Scheme | |
| MXPA99004331A (es) | Vectores de expresion mejorados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |